Segulah Medical Acceleration
Segulah Medical Acceleration is a Stockholm-based growth and venture investor that takes minority stakes in Nordic and European medical device, diagnostics, life-science tools and digital-health companies with commercial-stage products, spun out of the Segulah private equity group.
Key facts
Recent exits
Coverage notes
1 fund tracked, 9 portfolio companies (8 active · 1 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
9 companiesFunds & portfolio
Every fund Segulah Medical Acceleration has raised, with its portfolio companies. Hand-checked from public filings.
Segulah Medical AccelerationLife Sciences VC2021 · 5yr8 active · 1 realized
Unrealized
8 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech |  Sweden | 2025 | |
| HealthTech | Sweden | 2023 | |
| MedTech | Sweden | 2021 | |
| Biotech | Sweden | 2022 | |
| MedTech |  Germany | 2024 | |
| MedTech |  UK | 2021 | |
| MedTech | Sweden | 2023 | |
| MedTech | UK | 2021 |
Sweden· Entry 2025Sweden· Entry 2023Sweden· Entry 2021Sweden· Entry 2022Germany· Entry 2024UK· Entry 2021Sweden· Entry 2023UK· Entry 2021Saved GPs appear in your watchlist, one click from your workspace.
About Segulah Medical Acceleration
Segulah Medical Acceleration is the sole Nordic GP fully dedicated to medtech commercialisation with SEK 1.25-1.3 billion (~€110-125 million) of assets under management as of December 2024 (initial commitments c. SEK 1.2 billion), headquartered in Stockholm. The firm was founded in 2021 as an independent medtech specialist established with backing from leading Nordic institutions and prominent private investors. Segulah Medical operates independently from Segulah Advisor (Nordic buyout firm) despite shared Segulah heritage branding.
Investment thesis
Segulah Medical Acceleration deploys capital through one active fund (Segulah Medical Acceleration Fund I) plus co-investment sleeves, targeting medtech-only growth equity that provides early commercialisation capital (SEK 20-150 million ticket / ~€2-15 million) for medtech innovators transitioning from clinical validation to market scale. Sector focus spans medical devices, diagnostics, life science tools, digital health and healthcare technology and surgical and wound care. Geographic deployment is Europe with Nordic emphasis (Sweden, Denmark, Norway, Germany, UK) plus selective US. The medtech-only specialisation combines in-house operating expertise with an external network of medtech-industry veterans accelerating go-to-market.
Recent activity
Recent realised exits include healthcare technology (2024) and diagnostics (2026). Recent acquisitions include a wound care partnership (2024) and diagnostics CEO appointment and build (2024). The platform continues active deployment across the Nordic medtech commercialisation mandate. Detailed buyer names and multiple data available on Pro at €29/month.
Similar firms
Other private equity firms tracked on GP Intel.
Get the full picture on Segulah Medical Acceleration.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in